New hope for cancer patients battling treatment side effect that lowers survival
NCT ID NCT06956547
Summary
This program provides expanded access to an investigational drug called nogapendekin-alfa inbakicept (NAI) for adults with solid tumors. It aims to treat low lymphocyte counts (lymphopenia), a common and serious side effect of chemotherapy, immunotherapy, or radiation that can reduce survival. The main goal is to see if NAI can reverse this low count and keep it in a normal range, potentially helping patients live longer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOPENIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chan Soon - Shiong Institute for Medicine
AVAILABLEEl Segundo, California, 90245, United States
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.